◼ Archived
Business
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Phase 3 Trials
7 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
◼ Archived
Business
🔮 fades ✓
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
◼ Archived
Health
🔮 fades ✗
Common arthritis pill repurposed to boost hair regrowth in alopecia patients
Upadacitinib, a medication originally used for arthritis, has demonstrated efficacy in promoting hair regrowth for patients with severe alopecia areata.
◼ Archived
Business
🔮 fades ✗
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
FDA scientists are disputing efficacy claims regarding Capricor Therapeutics' Phase 3 Duchenne muscular dystrophy cell therapy, triggering a stock plunge.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.